Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia

Journal of Microbiology, Immunology and Infection

Volumn 44, Issue 4, 2011, Pages 258-264

  Lu, Ching Lan ^a   Lin, Yu Hui ^b   Wong, Wing Wai ^c   Lin, Hsi Hsin ^d   Ho, Mao Wang ^e   Wang, Ning Chi ^f   Hsieh, Szu Min ^a   Sheng, Wang Huei ^a   Hung, Chien Ching ^a   Chen, Mao Yuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d E DA HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Atazanavir; Combination antiretroviral therapy; HIV infection; Hyperlipidemia

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; IMMUNOLOGICAL PARAMETERS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PROSPECTIVE STUDY; RASH; TRIACYLGLYCEROL BLOOD LEVEL; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERLIPIDEMIAS; MALE; OLIGOPEPTIDES; PROSPECTIVE STUDIES; PYRIDINES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 79959566643     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2010.08.003     Document Type: Article

References (42)

1. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Dube M.P. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000, 31:1467-1475.
3. Hadigan C., Meigs J.B., Corcoran C., Rietschel P., Piecuch S., Basgoz N., et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130-139.
4. Thiébaut R., Daucourt V., Mercié P., Ekouévi D.K., Malvy D., Morlat P., et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000, 31:1482-1487.
5. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Chisholm D.J., Cooper D.A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
6. Lo Y.C., Chen M.Y., Sheng W.H., Hsieh S.M., Sun H.Y., Liu W.C., et al. Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study. HIV Med 2009, 10:302-309.
7. Friis-Møller N., Reiss P., Sabin C.A., Weber R., Monforte A., et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735. DAD Study Group.
8. Thiebaut R., Dabis F., Malvy D., Jacqmin-Gadda H., Mercie P., Valentin VD Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). J Acquir Immune Defic Syndr 2000, 23:261-265.
9. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003, 17(Suppl 1):S141-S148.
10. Calza L., Manfredi R., Farneti B., Chiodo F. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents 2003, 22:54-59.
11. Calza L., Manfredi R., Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004, 3:10-14.
12. Savès M., Raffi F., Capeau J., Rozenbaum W., Ragnaud J.M., Perronne C., et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002, 34:1396-1405.
13. Mulligan K., Grunfeld C., Tai V.W., Algren H., Pang M., Chernoff D.N., et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23:35-43.
14. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
15. Manfredi R. Management of dyslipidemia in patients with HIV disease. Clin Microbiol Infect 2000, 6:579-584.
16. Lenhard J.M., Croom D.K., Weiel J.E., Winegar D.A. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000, 20:2625-2629.
17. Lenhard J.M., Furfine E.S., Jain R.G., Ittoop O., Orband-Miller L.A., Blanchard S.G., et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000, 47:121-129.
18. Liang J.S., Distler O., Cooper D.A., Jamil H., Deckelbaum R.J., Ginsberg H.N., et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001, 7:1327-1331.
19. Friis-Møller N., Sabin C.A., Weber R., d'Arminio Monforte A., El-Sadr W.M., Reiss P., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
20. Noor M.A., Parker R.A., O'Mara E., Grasela D.M., Currie A., Hodder S.L., et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004, 18:2137-2144.
21. Noor M.A., Flint O.P., Maa J.F., Parker R.A. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006, 20:1813-1821.
22. Becker S. Atazanavir: improving the HIV protease inhibitor class. Expert Rev Anti Infect Ther 2003, 1:403-413.
23. Sanne I., Piliero P., Squires K., Thiry A., Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003, 32:18-29.
24. Cahn P.E., Gatell J.M., Squires K., Percival L.D., Piliero P.J., Sanne I.A., et al. Atazanavir-a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic) 2004, 3:92-98.
25. Haas D.W., Zala C., Schrader S., Piliero P., Jaeger H., Nunes D., et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003, 17:1339-1349.
26. Jemsek J.G., Arathoon E., Arlotti M., Perez C., Sosa N., Pokrovskiy V., et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006, 42:273-280.
27. Soriano V., García-Gasco P., Vispo E., Ruiz-Sancho A., Blanco F., Martín-Carbonero L., et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008, 61:200-205.
28. Busti A.J., Bedimo R., Margolis D.M., Hardin D.S. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med 2008, 56:539-544.
29. Nguyen S.T., Eaton S.A., Bain A.M., Rahman A.P., Payne K.D., Bedimo R., et al. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Pharmacotherapy 2008, 28:323-330.
30. Guffanti M., Caumo A., Galli L., Bigoloni A., Galli A., Dagba G., et al. Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. Eur J Endocrinol 2007, 156:503-509.
31. Gatell J., Salmon-Ceron D., Lazzarin A., Van Wijngaerden E., Antunes F., Leen C., et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007, 44:1484-1492.
32. Parker R.A., Wang S., Meyers D., Fenderson W., Mulvey R., Leet J., et al. Differentiation of HIV protease inhibitors in models of lipid and glucose metabolism and gene expression in adipocytes [abstract 100]. Antiviral Ther 2001, 6(Suppl 4):67.
33. Wang S., Mulvey R., Liang N., Leet J., Flint O., Parker R.A. Differentiation of atazanavir from other HIV-protease inhibitors in preclinical models of glucose uptake, lipogenesis, and proteasome function [abstract 10]. Antiviral Ther 2002, 7:L6.
34. Wood R., Phanuphak P., Cahn P., Pokrovskiy V., Rozenbaum W., Pantaleo G., et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004, 36:684-692.
35. Talmud P.J., Hawe E., Martin S., Olivier M., Miller G.J., Rubin E.M., et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002, 11:3039-3046.
36. Merkel M., Loeffler B., Kluger M., Fabig N., Geppert G., Pennacchio L.A., et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005, 280:21553-21560.
37. Chang S.Y., Ko W.S., Kao J.T., Chang L.Y., Sun H.Y., Chen M.Y., et al. Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan. Clin Infect Dis 2009, 48:832-835.
38. Möbius U., Lubach-Ruitman M., Castro-Frenzel B., Stoll M., Esser S., Voigt E., et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005, 39:174-180.
39. O'Mara E.M., Mummaneni V., Burchell B., Randall D., Geraldes M. Relationship between uridine diphosphate-glucuronosyl transferase (UDP-GT) 1A1 genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinivir [abstract 1645]. Abstract book of the 40th interscience conference on antimicrobial agents and chemotherapy 2000, ASM Press, Herndon, VA.
40. Sulkowski M.S. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004, 38(Suppl 2):S90-S97.
41. Pineda J.A., Palacios R., Rivero A., Abdel-kader L., Márquez M., Cano P., et al. Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. J Antimicrob Chemother 2006, 57:1016-1017.
42. Pérez-Elías M.J., Gatell J.M., Flores J., Santos J., Vera-Médez F., Clotet B., et al. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients. HIV Clin Trials 2009, 10:269-275.